Format

Send to

Choose Destination
Eur J Clin Pharmacol. 2011 May;67 Suppl 1:17-27. doi: 10.1007/s00228-010-0931-1. Epub 2010 Nov 11.

Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Author information

1
Department of Biochemistry and Medical Biotechnologies, University Federico II of Naples and CEINGE Biotecnologie Avanzate, Via Gaetano Salvatore 486, Naples, Italy. russor@ceinge.unina.it

Abstract

Genetic differences among individuals can explain some of the variability observed during drug treatment. Many studies have correlated the different pharmacological response to genetic variability, but most of them have been conducted on adult populations. Much less attention has been given to the pediatric population. Pediatric patients constitute a vulnerable group with regard to rational drug prescribing since they present differences arising from the various stages of development. However, only a few steps have been made in developmental pharmacogenomics. This review attempts to describe the current methods for pharmacogenetic and pharmacogenomic studies, providing some of the most studied examples in pediatric patients. It also gives an overview on the implication and importance of microRNA polymorphisms, transcriptomics, metabonomics, and proteomics in pharmacogenetics and pharmacogenomics studies.

PMID:
21069522
DOI:
10.1007/s00228-010-0931-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center